KALA BIO, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by KALA BIO, Inc. (Nasdaq: KALA) on January 2, 2026, covering events occurring on December 26, 2025. The filing addresses the resolution of a debt settlement with Oxford Finance, LLC.
Key Financial Metrics
- Debt Settlement Payment: $2.0 million paid to Oxford Finance, LLC on December 26, 2025.
- Total Liability Released: Approximately $10.6 million in aggregate liability was settled and released upon payment.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, profit, operating cash flow, or margins.
- Liquidity: The filing does not disclose current cash balances or liquidity ratios.
Material Changes
The Company satisfied all obligations under a Loan Settlement Agreement entered into on November 25, 2025, which resolved events of default under a Loan and Security Agreement dated May 4, 2021. The $2.0 million payment extinguished the remaining liability, which had grown to approximately $10.6 million.
Outlook, Risks, and Management Commentary
Management confirmed that the payment fully satisfied the Company's obligations to Oxford Finance, LLC. The filing does not provide forward-looking guidance, updated risk factors, or commentary on future financial performance beyond the resolution of this specific debt instrument.
Investor Verification Checklist
- Verify the impact of the $2.0 million cash outflow on the Company's current cash position and liquidity runway.
- Confirm that no other events of default exist under the Company's remaining debt agreements.
- Review the Company's most recent 10-Q or 10-K for updated revenue and burn rate metrics not included in this 8-K.
- Assess whether the settlement of the $10.6 million liability improves the Company's balance sheet leverage ratios.